Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.35 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6073481 | 0.81 | HASPIN (0.41) | MEN1KMT2AHASPINNTRK1 | |
| SCHEMBL29827832 | 0.81 | CCR1 (0.38) | MEN1KMT2AHASPIN | |
| SCHEMBL15263560 | 0.81 | CCR1 (0.38) | MEN1KMT2AHASPIN | |
| SCHEMBL25230105 | 0.78 | MEN1 (0.38) | MEN1KMT2ALMNAAHRSMN1; SMN2 | |
| SCHEMBL15507399 | 0.78 | MEN1 (0.36) | MEN1KMT2AHASPINNTRK1 | |
| SCHEMBL6073725 | 0.75 | NCF1 (0.39) | MEN1KMT2ALMNAAHRKDM4E | |
| SCHEMBL24558656 | 0.74 | MEN1 (0.45) | MEN1KMT2ALMNAAHRSMN1; SMN2 | |
| SCHEMBL27103126 | 0.74 | KDM4E (0.41) | SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL22612727 | 0.74 | KDM4E (0.35) | MEN1KMT2ALMNASMN1; SMN2KDM4E | |
| SCHEMBL3293161 | 0.74 | MEN1 (0.41) | MEN1KMT2ALMNASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10188642-B2 | Pharmacologically active compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-01-29 | — | — | US | disclosed |
| US-10188642-B2 | Pharmacologically active compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-01-29 | — | — | US | disclosed |
| US-20180117032-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| US-20180117032-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| US-20180117032-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| US-9895364-B2 | Pharmacologically active compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-02-20 | — | — | US | disclosed |
| US-9895364-B2 | Pharmacologically active compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-02-20 | — | — | US | disclosed |
| US-9895364-B2 | Pharmacologically active compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-02-20 | — | — | US | disclosed |
| EP-2892890-B1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS | CANCER RES TECH LTD (GB) | 2017-11-22 | — | — | EP | disclosed |
| EP-2892890-B1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS | CANCER RES TECH LTD (GB) | 2017-11-22 | — | — | EP | disclosed |
| US-20150218181-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-08-06 | — | — | US | disclosed |
| US-20150218181-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-08-06 | — | — | US | disclosed |
| US-20150218181-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-08-06 | — | — | US | disclosed |
| EP-2892890-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS | Cancer Research Technology Ltd (GB) | 2015-07-15 | — | — | EP | disclosed |
| WO-2014037751-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-03-13 | — | — | WO | disclosed |
| WO-2014037751-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-03-13 | — | — | WO | disclosed |
| US-7053070-B2 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2006-05-30 | — | — | US | disclosed |
| US-20030073668-A1 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | BOOTH RICHARD JOHN (US) | 2003-04-17 | — | — | US | disclosed |
| EP-1254137-A1 | PYRIDO 2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001055147-A1 | PYRIDO[2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218181-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS | BUB1B, BUB1, PLK1 | MEN1 472/4885KMT2A 3420/4885LMNA 1217/4885 |
| US-20180117032-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS | BUB1B, BUB1, PLK1 | MEN1 472/4885KMT2A 3420/4885LMNA 1217/4885 |
| US-10188642-B2 | Pharmacologically active compounds | BUB1B, BUB1, PLK1 | MEN1 472/4885KMT2A 3420/4885LMNA 1217/4885 |
| US-20030073668-A1 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | CDK9, CDK19, CDK3 | MEN1 4797/4885KMT2A 2672/4885LMNA 2415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.